Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 42

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 42
---
 tolimidone for any field.

Pursuant to the terms of the
License Agreement, we issued to Melior 1,417 Depositary Shares in upfront consideration, and agreed to issue the same to Bukwang. In addition,
we are obligated to pay single digit tiered royalties on net sales of tolimidone to Melior, with Melior agreeing to pay to Bukwang 50%
of such royalties pursuant to a royalty agreement.

Under the Melior License Agreement,
we, at our own cost, have the right to control the prosecution, maintenance and enforcement of the tolimidone patents, while Melior has
certain step-in rights if we elect not to prosecute and maintain such tolimidone patents. The Melior License Agreement may be terminated
by Melior if we fail to meet various development diligence obligations.

In connection with the License
Agreement, on November 22, 2023, Melior and Bukwang entered into an amendment to the license agreement with Bukwang, or the Bukwang License.
Under the amendment, the Bukwang License terminated in its entirety and Bukwang transferred to Melior all rights, titles and interests
to certain INDs, know-how and data, and patents relating to tolimidone.

Under the Bukwang Amendment,
Melior and Bukwang entered into a royalty agreement pursuant to which Bukwang shall be entitled to 50% of all payments Melior receives
under the License Agreement, including: (i) 50% of the equity issued by us under the License Agreement, and (ii) 50% of the royalties
that we will pay to Melior. Further, under the royalty agreement, Bukwang will pay to Melior $100,000 in consideration for Melior’s
waiver of Bukwang’s obligation to pay patent costs pursuant to the Bukwang License, and Melior will take back responsibility for
all tolimidone patent prosecution and maintenance costs.

Additional Information

Additional information regarding the Company, including
our intellectual property, sales and marketing, research and development capabilities, competitors and regulatory environment, is set
forth in our Annual Report on Form 20-F for the year ended December 31, 2024 and the other documents we incorporate by reference herein.

| 29 |

<div align='center'>PRINCIPAL SHAREHOLDERS</div>

The following table sets forth information,
to our knowledge, as of December 1, 2025, regarding the beneficial ownership of Ordinary Shares (including